Skip to content

    Remus Pharma.

    REMUS
    Healthcare·11 Nov 2025
    Management Summary

    Remus Pharma reported strong H1 FY26 results with consolidated revenue up 47% YoY to ₹400 crores, driven by growth in both standalone and subsidiary operations. The company is strategically shifting towards higher-margin B2C segments, with its share increasing from 4% to 13%. However, consolidated margins remain lower due to the significant contribution from the high-volume, low-margin US RLD distribution business, which accounts for approximately 80% of total revenue.

    Highlights

    5

    • Consolidated revenue grew 47% YoY to ₹400 crores.

    • Standalone revenue grew 24% YoY to ₹47 crores.

    • Consolidated operational EBITDA increased 28% YoY to ₹27 crores, with standalone EBITDA up 31% to ₹15 crores.

    • B2C business revenue share significantly increased from 4% last year to 13% in H1 FY26, with a target of 18-20% by year-end.

    • Secured 37 new approvals in the ASEAN region and initiated product registration in Algeria, expanding international footprint.

    Concerns

    2

    • Consolidated EBITDA margin of 6.75% and PAT margin of 5.4% are significantly lower than standalone margins (31.56% EBITDA, 25.59% PAT) due to the high-volume, low-margin US subsidiary business.

    • The company is an 'asset-light' model without in-house manufacturing, which raised analyst questions regarding long-term margin confidence.

    Key financials

    Single quarter

    11 metrics
    1. 01Consolidated Revenue₹400 Cr+47%YoY
    2. 02Consolidated Operational EBITDA₹27 Cr+28.0%YoY
    3. 03Consolidated EBITDA Margin6.8%
    4. 04Consolidated Net Profit (PAT)₹22 Cr+21%YoY
    5. 05Consolidated PAT Margin5.4%

    Segment breakdown

    B2C Business
    13% Revenue Share
    B2B Business
    87% Revenue Share
    Emerging Market B2B
    32% EBITDA Margin
    Emerging Market B2C
    35% EBITDA Margin
    US Subsidiary (RLD Distribution)
    80% Revenue Share (Consolidated)40% Revenue Growth (H1 YoY)
    List

    Capital allocation

    1
    high confidence
    CategoryHeadline
    M&A

    US Subsidiary (Espee)

    acquisition · integrated

    Guidance & targets

    4
    CategoryTargetPriority
    Market Share
    B2C Revenue Share
    18-20%
    		Medium
    Market Share
    B2C Revenue Share
    20-25%
    		High
    Profitability
    Consolidated PAT Margin
    8-10%
    		Medium
    Geographical Expansion
    New Countries Added
    3
    		High

    B2C Revenue Share Growth

    End of FY26
    Current13% of H1 FY26 revenue
    Target18-20% by end of FY26

    Why it matters

    This is a key driver for overall margin improvement and reflects the success of the company's strategic shift.

    As we are talking about H1 right now, our B2C business growth grew from 4% last year to 13% for H1 so we are still waiting for considerable growth from 13% to probably 18 to 20% before the end of this financial year.

    How to verify

    key_financials.segment_breakdown[name='B2C Business'].metrics[label='Revenue Share']

    Risks & concerns

    1
    RiskSeverity

    Margin Dilution from US Subsidiary

    The US subsidiary's high-volume, low-margin RLD distribution business, contributing ~80% of consolidated revenue, significantly dilutes the overall consolidated EBITDA and PAT margins, making the company's profitability appear lower than its high-margin emerging market segments. — Analyst acknowledged

    medium

    Q&A highlights

    7

    “Aachal, not all countries have those capabilities of having an in-house manufacturing and be self-reliant on manufacturing of pharma products. But I will consider it one of the countries I recently a month back I visited was Algeria where what we have been doing, yes they encourage a local manufacturing of the product there but at the same point of time a technical know-how is more important than any country who is manufacturing pharma products for which what we have been doing is we are doing a tech transfer and a licensing deal with them where every product that in future if they manufacture it at their end we get the royalties on the product that they sell along with that we get a licensing fee and a know-how transfer as well.”

    Analyst questioned the company's ability to compete on cost against local manufacturers in Africa, prompting management to explain their strategy of tech transfer, licensing, and focus on niche products for private markets.

    asked by Aachal Jalan

    2 min read6 chapters

    Detailed Narrative

    01

    Strong H1 FY26 Financial Performance

    Remus Pharmaceuticals reported robust financial results for H1 FY26. On a standalone basis, revenue from operations stood at ₹47 crores, reflecting a 24% year-on-year growth. Operational EBITDA reached ₹15 crores, marking a 31% increase with EBITDA margins of 31.56%. Net profit was ₹12 crores, representing a 31% year-on-year increase and a PAT margin of 25.59%. On a consolidated basis, revenue from operations was ₹400 crores, a 47% growth year-on-year, with operational EBITDA at ₹27 crores, up 28%.

    02

    Strategic Shift Towards High-Margin B2C Segment

    The company is actively pursuing a strategic shift towards higher-margin B2C segments. The B2C business demonstrated strong momentum, increasing its revenue share from 4% last year to 13% in H1 FY26. Management aims to further grow the B2C contribution to 18-20% by the end of FY26 and 20-25% within the next 1.5 years, anticipating better gross margins from this segment compared to the traditional B2B business.

    03

    Dual Business Model: Emerging Markets vs. US Subsidiary

    Remus operates with a dual business model. Its emerging market segments, including standalone operations and subsidiaries in Bolivia and Guatemala, focus on niche, high-margin products, achieving B2B EBITDA margins of 32-33% and B2C EBITDA margins of 35%+. In contrast, the US subsidiary (Espee), which accounts for approximately 80% of consolidated revenue, specializes in high-volume, lower-margin RLD (Reference Listed Drug) distribution, primarily serving big pharmaceutical conglomerates for research purposes. This mix results in a consolidated EBITDA margin of 6.75% and a PAT margin of 5.4%.

    04

    US Subsidiary's Role and Investment Recovery

    The US subsidiary, acquired in 2024, is a key component of Remus's strategy, despite its lower margin profile. It functions as a high-ROE, asset-light business, requiring no significant capital infusion. Management highlighted that 80-90% of the investment made in acquiring this subsidiary has already been recovered through profits, underscoring its financial efficiency and contribution to overall turnover.

    05

    International Expansion and Product Portfolio Diversification

    Remus is actively expanding its international footprint and diversifying its product portfolio. The company successfully participated in a national tender in Nicaragua, securing awards for two key products. Product registration activities have been initiated in the Algerian market, and 37 new approvals were secured in the ASEAN region. A significant milestone was the launch of Rivastigmine patches across multiple markets, marking entry into a new therapeutic segment. Over 95% of the company's exports are from advanced and niche formulations.

    06

    Future Profitability and Margin Improvement Targets

    While the consolidated PAT margin for H1 FY26 stood at 5.4%, management is optimistic about future improvements, eyeing a consolidated PAT margin of 8-10% eventually. This improvement is expected to be driven by the increasing contribution of the higher-margin B2C business and the operationalization of new subsidiaries, with potential realization within the next 1-2 years. The company also anticipates a shift in revenue mix, with emerging markets gradually increasing their share relative to the US subsidiary over time.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.